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NeonateStreptococcus pneumoniae is a leading cause of pneumonia, the most common cause of childhood death.
Papua New Guinean children experience high rates of nasopharyngeal pneumococcal colonization within
weeks of birth, predisposing them to pneumococcal disease. In a trial to determine the safety and
immunogenicity of early infant vaccination with 7-valent pneumococcal conjugate vaccine (7vPCV),
we investigated the impact of early schedules on pneumococcal carriage.
Infants were randomized at birth to receive 7vPCV in a 0–1–2-month (n = 101) or a 1–2–3-month
(n = 105) schedule or no 7vPCV (n = 106). All children received 23-valent pneumococcal polysaccharide
vaccine at age 9 months. We cultured nasopharyngeal swabs (NPS) collected at ages 1, 2, 3, 4 weeks and
3, 9, 18 months, and middle ear discharge if present. Pneumococcal serotypes were identified by the
Quellung reaction.
A total of 1761NPSwere cultured. The prevalence of pneumococcal carriagewas 22%at 1 weekof age, rising
to 80% by age 3 months and remained >70% thereafter, with high-density carriage in 42% of pneumococcus-
positive samples. We identified 63 different serotypes; 43% of isolates from controls were 13vPCV sero-
types. Therewere no significant differences in 7vPCV serotype carriage between 7vPCV recipients and con-
trols at any age (22% vs. 31% at 9 months, p = 0.2). At age 9 months the prevalence of non-7vPCV carriage
was 17% higher in 7vPCV recipients (48%) than in controls (25%, p = 0.02). More non-7vPCV serotypes were
isolated from ear discharge in 16 7vPCV recipients than from 4 controls (48% vs. 25%, p = 0.13).
The limited impact of neonatal or accelerated infant 7vPCV schedules on vaccine serotype carriage is
probably due to the early onset of dense carriage of a broad range of pneumococcal serotypes. While
serotype-independent pneumococcal vaccines are needed in high-risk populations, the underlying envi-
ronmental factors and sources of infection must be investigated.
http://clinicaltrials.gov/ct2/show/NCT00219401.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).), peter.
hotmail.
a.edu.au
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Pneumonia is the most common cause of death in children
worldwide [1]. Streptococcus pneumoniae (the pneumococcus) is a
major cause of pneumonia as well as other invasive diseases such
as meningitis and bacteraemia. It is also responsible for non-
invasive diseases such as otitis media (OM) which can result in
hearing loss [2]. Nasopharyngeal carriage of S. pneumoniae predis-
poses individuals to pneumococcal diseases; early carriage in
infants is associated with increased risk of OM and is found in pop-
ulations with a high incidence of invasive pneumococcal disease
(IPD) [3,4]. In the highlands of Papua New Guinea (PNG), coloniza-
tion of the nasopharynx starts within weeks of birth, with all
infants acquiring S. pneumoniae by 3 months of age and high car-
riage rates being maintained throughout childhood [4–6]. Pneumo-
nia remains the most common cause of death and reason for
hospitalization in childhood in PNG [7,8]. Mortality due to acute
lower respiratory infections (ALRI), in particular pneumonia, was
reported in 1999 to be highest in the first year of life, with 56%
of deaths in children under the age of five years occurring before
six months of age [9].
Pneumococcal conjugate vaccines (PCVs) have been used to
combat pneumococcal disease in infants. A protein carrier is
linked to an otherwise T cell-independent polysaccharide antigen
to evoke an immunological response and enhance long-term
memory to serotypes included in the vaccines. The introduction
and widespread use of PCVs in first world countries has resulted
in a significant decline in nasopharyngeal carriage and IPDs
caused by vaccine serotypes in children under the age of 2 years.
PCVs also indirectly protect unvaccinated people through herd
immunity [10–12]. Encouraging results have also been seen in
third world settings where PCVs have been trialled [13,14].
PCV given at ages 6, 10 and 14 weeks in third world countries
and 2, 4 and 6 months with a booster in the second year of life
in first world countries are immunogenic and reduce nasopha-
ryngeal carriage of pneumococcal serotypes included in PCVs
[10,15]. In addition, a pneumococcal polysaccharide vaccine has
previously been shown to reduce pneumonia mortality in PNG
children when given between the ages of 6 months and 5 years
[16]. However, in populations where carriage occurs within
weeks of birth and where morbidity and mortality due to ALRI
are highest in the first 6 months of life, interventions at a very
young age are necessary. Hence, a trial evaluating an accelerated
schedule including a neonatal PCV dose was carried out to assess
the safety and immunogenicity of the seven-valent PCV (7vPCV)
in children living in the Asaro Valley, Eastern Highlands Pro-
vince, PNG. We have previously reported that neonatal and early
infant immunization with 7vPCV is safe and immunogenic [17].
We now aim to describe the effect of 7vPCV on nasopharyngeal
carriage of pneumococci and pneumococcal serotypes when
given either in a 0–1–2 or 1–2–3-month schedule. We also look
at the effect of 7vPCV on pneumococci isolated from ear dis-
charge swabs of children with tympanic membrane perforation
(TMP) due to OM.2. Methods
A detailed description of the study site and population, process
of recruitment, assent and consent, enrolment, randomisation
method, allocation concealment, study staff and participant blind-
ing, laboratory staff blinding, and participant characteristics by
allocated group, immunization and follow-up for primary out-
comes are reported elsewhere [17,18]. A brief overview is given
below.2.1. Study design
The neonatal pneumococcal conjugate vaccine trial was carried
out between 2005 and 2009. It was an open-label randomized con-
trolled trial of 7vPCV (Wyeth/Pfizer; serotypes 4, 6B, 9V, 14, 18C,
19F & 23F) given at the ages of 0, 1 and 2 months (neonatal group)
or at 1, 2 and 3 months (infant group) and a group that received no
7vPCV (control group). Study design and procedures are reported
elsewhere [18]. All the children received other vaccinations
according to the PNG Expanded Programme on Immunization
[18,19] and 23-valent pneumococcal polysaccharide vaccine
(PPV, Merck & Co, Inc; serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V,
10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F)
was given at 9 months of age. Participants were followed up to
the age of 18 months.
Participant recruitment is reported in Pomat et al. [17]. Inclu-
sion criteria for enrolment were: the intention to remain in the
study area for at least 2 years, a birth weight > 2000 grams, no
acute neonatal infection, no severe congenital abnormality, and
born in Goroka General Hospital (GGH) or brought to GGH within
24 h of birth. Children of mothers known to be HIV-positive were
excluded.
2.2. Nasopharyngeal swab collection
Infants were seen either at home or at the PNG Institute of
Medical Research (PNGIMR) clinic at ages 1, 2, 3 and 4 weeks and
3, 9 and 18 months. Nasopharyngeal swabs (NPS, rayon-tipped
swabs with metal shaft. Medical Wire and Equipment, Wiltshire,
England) were collected and processed according to WHO recom-
mended procedures for pneumococcal carriage studies [20]. The
swab was inserted into the nasopharynx until resistance was met
and then rotated for five seconds. Immediately following collec-
tion, the swab was placed in 1 ml of skim milk tryptone glucose
glycerol broth (STGGB) [20]. The swabs were kept cool in an insu-
lated container with ice packs and taken to the PNGIMR bacteriol-
ogy laboratory within 2 h and stored at 80 C until processed.
Ear discharge swabs (Amies Copan, Interpath Services, Australia)
were collected from children who had purulent ear discharge on
examination. Ear discharge swabs were placed directly into 1 ml
STGGB and transported and stored as for NPS.
2.3. Culture of nasopharyngeal swabs and ear swabs
Approximately 12% of NPS (235/1996) were lost following a
freezer thaw (details in results section). The remaining NPS were
cultured using standard bacteriological procedures [20] by labora-
tory staff blinded to PCV group. 10 ll aliquots of the NPS in STGGB
were streaked onto horse blood agar, chocolate agar, gentamicin
blood agar (5 lg/ml) and bacitracin chocolate agar (300 lg/ml).
Plates were incubated overnight (18–24 h) at 37 C in 5%
CO2-enriched atmosphere. Bacterial growth was quantified on
the plate as follows: 0, no growth; 1, <20 bacterial colonies; 2,
20–50 bacterial colonies; 3, 50–100 bacterial colonies; 4, confluent
growth on the primary streak of the plate; 5, confluent growth on
the primary streak of the plate and colonies on the second streak;
6, confluent growth in the secondary zone and colonies in the third
zone. A quantification code of 1–3 was considered low density
while 4–6 was considered high density. Four suspected morpho-
logically distinct individual colonies of pneumococci on the pri-
mary plate (a-haemolytic low convex, plateau or draughtsman-
shaped colonies) were picked and tested for optochin (5 lg
ethylhydrocupreine, Oxoid, Australia) sensitivity. A zone of growth
around the optochin disc of P14 mm diameter was considered
38 C. Aho et al. / Vaccine Reports 6 (2016) 36–43positive for S. pneumoniae. The bile solubility test was done on
optochin-resistant colonies (<14 mm) to confirm S. pneumoniae.2.4. Serotyping
Pneumococcal serotyping was done on all pneumococcal iso-
lates by the Quellung reaction with antisera from Statens Serum
Institut, Denmark. Serotyping on all 4 subcultured colonies was
performed with all identified serotypes reported once per sample.
Relevant serogroups in the 7vPCV, namely 6, 9, 18, 19 and 23
were factor-typed (to the serotype level) along with the non-
7vPCV serogroup 7. Not all factor sera were available at the time
of study.
A representative sample (n = 134) of typed isolates was sent to
Queensland Public Health laboratory for factor typing and serotype
confirmation by the Quellung reaction: all serotyping results were
concordant.2.5. Statistical analysis
The primary endpoint for analysis was nasopharyngeal carriage
rates of any S. pneumoniae, 7vPCV serotypes (VT: 4, 6B, 9V, 14, 18C,
19F, 23F) and non-7vPCV (NVT) serotypes. Vaccine-related sero-
types were included with NVT. 23PPV serotypes and non-23PPV
serotypes (all other) are reported where appropriate. Results were
aggregated according to serotype to calculate the prevalence and
proportions of individual serotypes among all serotypeable iso-
lates. Non-serotypeable pneumococci are reported separately to
the serotypeable isolates.
Chi-squared tests were used to assess between group differ-
ences in prevalence of VT and NVT serotypes at 1–4 weeks of age
and at 3, 9 and 18 months. If prevalence rates or serotype distribu-
tion did not differ significantly between infant and neonatal
groups, these were combined (vaccinated) for comparisons with
controls.2.6. Ethical considerations
Ethical clearance for the study was obtained from the PNGMed-
ical Research Advisory Committee and from the Princess Margaret
Hospital for Children Ethics Committee in Perth, Australia. The trial
is registered at ClinicalTrials.gov under registration number
NCT00219401 (http://clinicaltrials.gov/ct2/show/NCT00219401).Table 1
Prevalence of carriage of Streptococcus pneumoniae (Any Spn), high density S. pneumoniae (
infant and control groups by age.
Vaccine group Age of routine visits
1 week 2 weeks 3 weeks 4 w
n/nps (%)* n/nps (%) n/nps (%) n/
Neonatal PCV Any Spn 21/85 (24.7) 26/83 (31.3) 31/85 (36.5) 48
HD Spn 8/85 (9.4%) 10/83 (12.0) 10/85 (11.8) 28
VT Spn 5/85 (5.9) 7/83 (8.4) 12/85 (14.1) 14
NVT Spn 16/85 (18.8) 17/83 (20.5) 19/85 (22.4) 32
Infant PCV Any Spn 20/93 (21.5) 36/95 (37.9) 42/92 (45.7) 52
HD Spn 6/93 (6.5) 17/95 (17.9) 19/92 (20.7) 24
VT Spn 4/91 (4.4) 6/91 (6.6) 10/88(11.4) 15
NVT Spn 15/91 (16.5) 22/91 (24.2) 28/89 (31.5) 30
Control Any Spn 17/91 (18.7) 34/91 (37.4) 45/92 (48.9) 52
HD Spn 9/91 (9.9) 18/91 (19.8) 19/92 (20.7) 25
VT Spn 4/91 (4.4) 8/87 (9.2) 11/88 (12.5) 11
NVT Spn 11/91 (12.1) 22/89 (24.7) 23/88 (26.1) 35
Different Denominators in VT Spn and NVT Spn are due to the exclusion of indeterminat
and 6C).
* n/nps (%) = number positive/number of nasopharyngeal swabs cultured (%).3. Results
3.1. Study population characteristics
Of the 448 mothers who assented for their children to be
recruited into the study, 318 subsequently consented and were
randomized to neonatal (n = 104), infant (n = 105) and control
cohorts (n = 109). Six newborns were subsequently excluded on
medical grounds. Details of loss to follow-up and protocol viola-
tions have been described elsewhere [18]. There were two deaths
during the study period that were unrelated to study vaccines
and 14 protocol violations relating to allocated immunization
schedule [17]. No parent refused collection of NPS from their child
at any time point. Supplementary Table 1 shows the distribution of
collected samples that were cultured by age and group allocation.
The proportion of samples that could not be cultured ranged from
7% to 18% with no significant differences between allocated groups
or over time, although there were fewer thawed samples at ages 9
and 18 months than in younger children. Of the 312 children
enrolled in the study, 309 (99 in neonatal, 104 in infant and 106
in control cohorts) had at least 1 sample collected during routine
follow-up visits that was available for culture; 80% had culture
data available from 5 or more samples with no significant differ-
ence between groups. Of the NPS cultured there was a lower pro-
portion from male participants in the neonatal group (231/552,
42%) than in either the infant vaccination group (349/609, 57%)
or controls (379/600, 63%) (Chi-squared = 55.73, p < 0.0001, 2df).
Nevertheless, the gender distribution at each follow-up visit was
consistent with the gender distribution of study participants
reported previously [17,18].
3.2. Age-specific prevalence of pneumococcal carriage by allocated
group
We cultured a total of 552, 609 and 600 NPS collected during
routine follow-up visits of children in the neonatal, infant and con-
trol groups, respectively (Table 1). At 1 week of age, 22% (n = 58) of
children carried S. pneumoniae, increasing to 59% (n = 152) at
1 month of age and peaking at 9 months when 84% (n = 199) of
children carried S. pneumoniae (Table 1). There were no significant
differences in overall pneumococcal carriage rates between the
neonatal, infant and control cohorts at any time point (Fig. 1a).
Overall, 42% of pneumococcus-positive samples were high density,
and there were no differences in density of carriage betweenHD Spn), 7vPCV serotypes (VT Spn) and non-7vPCV serotypes (NVT Spn) in neonatal,
eeks 3 months 9 months 18 months Total
nps (%) n/nps (%) n/nps (%) n/nps (%) n/nps (%)
/80 (60.0) 63/74 (85.1) 65/75 (86.7) 52/70 (74.3) 306/552 (55.4)
/80 (35.0) 32/74 (43.2) 21/74 (28.4) 21/70 (30.0) 130/551 (23.6)
/79 (17.7) 16/74 (21.6) 14/71 (19.7) 13/70 (18.6) 81/547 (14.8)
/80 (40.0) 45/74 (60.8) 50/71 (70.4) 38/70 (54.3) 217/548 (39.6)
/84 (61.9) 70/84 (83.3) 72/83 (86.7) 64/78 (82.1) 356/609 (58.5)
/84 (28.6) 33/84 (39.3) 35/83 (42.2) 20/78 (25.6) 154/609 (25.3)
/80 (18.8) 17/80 (21.3) 20/83 (24.1) 21/77 (27.3) 93/590 (15.8)
/79 (38.0) 45/83 (54.2) 49/83 (59.0) 43/76 (56.6) 232/592 (39.2)
/95 (54.7) 67/82 (81.7) 62/79 (78.5) 50/70 (71.4) 327/600 (54.5)
/95 (26.3) 24/82 (29.3) 24/79 (30.4) 17/70 (24.3) 136/600 (22.7)
/94 (11.7) 21/81 (25.9) 24/78 (30.8) 15/69 (21.7) 94/588 (16.0)
/94 (37.2) 47/81 (58.0) 37/78 (47.4) 33/69 (47.8) 208/590 (35.3)
e serotypes like 6NF (NF = no factor type) and 6A/C (not discriminated between 6A
C. Aho et al. / Vaccine Reports 6 (2016) 36–43 39neonatal, infant and control cohorts (Fig. 1a). The prevalence of
non-serotypeable S. pneumoniae (failing to react with omni serum)
was 8% of all samples.
All available S pneumoniae isolates (Supplementary Table 2)
were serotyped to the serogroup level, and for VT, most were
grouped to the serotype level. Fifty-five serogroup 6 (5.5%) isolates,
one serogroup 18 (0.1%), twelve isolates from serogroup 19 (1.2%)
and six isolates of serogroup 23 (0.6%) were not resolved to sero-
type level and were not included in subsequent analyses or
counted towards the total serotypes. We were unable to discrimi-
nate 6C from 6A for 48 isolates due to non-availability of factor
type 6C in the laboratory in PNG. However, for 41 isolates typed(a)
(b)
(c)
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Fig. 1. (a) Prevalence of S. pneumoniae carriage, (b) VT (7vPCV) carriage and (c) NVT (
prevalence of high density carriage.as 6A in PNG, 6C was differentiated from 6A by PCR at the Menzies
School of Health Research in Darwin. Fig. 1b shows the prevalence
of VT and Fig. 1c, the prevalence NVT carriage in the neonatal,
infant and control cohorts at routine follow-up visits. At 3 months
of age, VT carriage prevalence was 22, 21 and 26 percent and NVT
carriage was 61, 54 and 58 percent in the neonatal, infant and con-
trol cohorts respectively (Table 1). There was no significant differ-
ence in VT or NVT carriage prevalence between vaccinated and
unvaccinated cohorts before the age of 9 months or at age
18 months (For example 3 months: VT Chi-squared 0.38, p = 0.54,
NVT Chi-squared = 0.001 p = 0.97; 18 months VT Chi-
squared = 0.003, p = 0.96; NVT Chi-squared = 0.82, p = 0.37.). How-1m 3m 9m 18m
1m 3m 9m 18m
Age
1m 3m 9m 18m
Age 
non-7vPCV) carriage by age according to vaccine cohort. Dark bars in (a) indicate
40 C. Aho et al. / Vaccine Reports 6 (2016) 36–43ever, differences were noted at age 9 months: the prevalence of
NVT carriage was significantly higher in the neonatal and infant
groups combined than in controls (64% (99/154) vs. 47% (37/78)
(Chi-squared = 5.39, 1df, p = 0.02, Table 1, Fig. 1c). Prevalence of
VT carriage at 9 months was lowest in the neonatal group (20%
(14/71)), 24% (20/83) in the infant group, and 31% (24/78) among
controls (Chi-squared 7vPCV recipients to controls = 1.64, 1df,
p = 0.2, Table 1, Fig. 1b).3.3. Serotype-specific data
Sixty-three distinct S. pneumoniae serogroups/serotypes were
identified in this study; 53 different serotypes/serogroups were
identified within the first month of life. The overall distribution
of serotypes in the neonatal, infant and control groups, all ages
combined, is provided in Supplementary Table 2. The top serotypes
in each group were: Neonatal 19F (11%), 15 (10%), 19A (8%), 23F
(5%), 6A/C (4%), 6B (3%), 16 (3%), 21 (3%) and 35 (3%); Infant 19F
(11%), 15 (6%), 6B (4%), 16 (4%), 6A/C (4%), 19A (4%), 35 (4%), 34
(3%) and 6A (3%); Control 23F (8%), 19F (8%), 15 (7%), 6A/C (7%),
19A (7%), 14 (5%), 35 (3%), 3 (3%), 6B (3%) and 16 (3%). At age
9 months, when there was the greatest impact of PCV on VT/NVT
carriage, there were no significant differences between 7vPCV
recipients and controls for individual serotypes, although serotype
19F tended to be isolated more often among controls than 7vPCV
recipients (Supplementary Table 3, Chi-squared 7vPCV recipients
to controls = 2.14, 1df, p = 0.14).
Overall, the proportion of fully characterised serotypeable
pneumococcal carriage isolates covered by the 7vPCV in the neona-
tal, infant and control cohorts was 25%, 26% and 28% respectively,
while the more recently licenced 13vPCV (which includes addi-
tional serotypes 1, 3, 5, 7F, 6A, 19A) covered 38%, 36% and 43% of
pneumococcal isolates, respectively. In the control cohort at age
9 months 39% of serotypeable isolates were covered by the 7vPCV
while 61% were covered by 13vPCV (Fig. 2). At 9 months, 7vPCV
recipients had significantly higher carriage of serotypes not
included in any licensed pneumococcal vaccine (depicted as
‘‘Other” in Fig. 2) than controls; neonatal 59%; infant 56%; control
36% (Chi squared = 6.9, 1df, p = 0.01).
Simultaneous carriage of multiple serotypes in pneumococcus-
positive samples (for which serotypes were fully differentiated)
was detected in 7% (20/293), 9% (28/325) and 11% (32/289) in
the neonatal, infant and control cohorts respectively.0
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Fig. 2. Proportion of pneumococcal serotypes in nasopharyngeal swabs covered by
7vPCV, 10vPCV, 13vPCV and 23PPV, and those not present in any licensed vaccine
(‘Other’), according to vaccine cohort at 9 months of age.3.4. Pneumococcal isolation rates from middle ear discharge
Swabs of middle ear discharge were collected from one or both
ears during 49 episodes of acute otitis media with perforation or
chronic suppurative otitis media (13 in neonatal group, 20 in infant
group, and 16 in controls) occurring in 36 children (11 neonatal, 14
infant, 11 control). The children were all aged >3.5 months and
those in the neonatal and infant groups had completed immuniza-
tion according to the allocation group. Pneumococcal isolation
rates from ear discharge were 46% (6/13), 65% (13/20) and 50%
(8/16) in neonatal, infant and control groups, respectively, with
no significant difference between groups. Three of the 27 pneumo-
coccal ear discharge isolates (all in the infant group) could not be
revived for serotyping. Three 7vPCV serotypes (3/16; 19%) were
isolated from ear discharge collected from controls and one each
in neonatal (1/13; 8%) and infant (1/20; 5%) cohorts (neonatal
+ infant vs. control; Fisher’s Exact test, p = 0.31). Non-7vPCV sero-
types were more commonly isolated from ear discharge collected
from children who had received 7vPCV than from controls, but this
was not significant (46%, 6/13 neonatal; 50%, 10/20 infant; 25%,
4/16 controls, (neonatal + infant (48%) vs. control (25%); Fisher’s
Exact test 0.10, p = 0.13). Notably, serotype 19A was isolated from
21% (7/33) of ear swabs collected from 7vPCV recipients compared
with 6% (1/16) among controls (neonatal + infant vs. control; Fish-
er’s Exact test p = 0.25). NVTs accounted for 86% of serotyped
pneumococci in the neonatal group, 91% in the infant group and
57% in controls (neonatal + infant vs. control; Fisher’s Exact test
p = 0.11). Of the 26 pneumococcal isolates with available serotype
data, the serotypes identified in the neonatal group were 3 (n = 2),
5, 18B, 19A (n = 2, one of which was isolated from same swab as
aforementioned serotype 3) and 23F. Serotypes in the infant group
were 11C (n = 2), 19A (n = 5), 19F, 35 (n = 2) and 45. In controls the
serotypes were 5, 6B, 18C, 19A, 19F, 20 (together with a non-
serotypeable isolate) and 24.4. Discussion
Our study is one of only two neonatal PCV studies worldwide.
The Kenyan neonatal study [21] reported carriage at two time
points in two PCV vaccinated groups whereas we report carriage
at 7 time points and include an unvaccinated control group, with
all infants in the study receiving an additional booster dose of
23PPV at 9 months.
We found early and high S. pneumoniae nasopharyngeal car-
riage increasing with age across the three cohorts of infants irre-
spective of vaccine schedule. The lack of a significant difference
in overall prevalence of pneumococci between vaccinated and con-
trol groups was also observed in Kenyan infants and other high risk
populations in Africa and Fiji where prevalence of carriage is high
[21–23]. Furthermore, pneumococcal carriage was dense in a high
proportion of pneumococcus-positive samples in our study regard-
less of their PCV vaccination status and high density is associated
with increased risk of disease [24]. Further studies investigating
the effect of PCV on density of carriage using quantitative PCR for
total bacterial load and species-specific load are needed in PNG.
The underlying mechanisms that foster and sustain the elevated
carriage in this population are unclear. However, possible sources
of respiratory pathogens could be contact with densely colonised
older siblings [25], the child’s mother [6] and adults with chronic
lung disease which is a prevalent condition in the highlands of
PNG [26]. Overcrowding is an important risk factor and was found
to be the strongest predictor of carriage in Australian Aboriginal
children [25]. Overcrowding in the highlands of PNG is common
and is also likely to be a factor driving high nasopharyngeal car-
riage transmission in this population. It is common for a family,
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a traditional highland house, which typically comprises just one
communal room with smoke from a wood fire in the centre of
the room [27]. Exposure to environmental tobacco smoke and
wood smoke from burning biomass fuel, a popular form of fuel
for cooking due to its affordability, may also contribute to high car-
riage rates by enhancing nasopharyngeal colonization [28,29]. In
an indoor air pollution study, Kirarock recorded significantly
higher levels of coarse particulate matter (PM10) released from
burning of biofuel in traditional highland houses than in semi-
permanent and permanent houses [27]. Hand hygiene can also
play a role in the acquisition and transmission of different sero-
types in children. Aboriginal children living in remote communities
were 3 times more likely to have nasal discharge and 23 times
more likely to have hand contamination with both S. pneumoniae
and H. influenzae than children attending urban day care centres
[30]. More needs to be done to increase public health awareness
on healthy living lifestyle and improving living conditions espe-
cially in the rural areas.
A total of sixty-three different pneumococcal serotypes/ser-
ogroups were detected over the duration of the study illustrating
the high diversity of serotypes present in this population. This is
likely to be an underestimate as factor sera were not available
for all serogroups. Pneumococcal isolates with indeterminate sero-
type, like 6A/C, were not counted as separate serotypes. Factor typ-
ing was not available in our previous studies in PNG; therefore this
is the first study to report any serotype-specific carriage data in
Papua New Guinean children. Overall, the high diversity of sero-
types in this population may limit the impact of limited valency
conjugate vaccines.
In this study there was a reduction in VT carriage in the vacci-
nated cohorts at 9 months of age, although not statistically signif-
icant, and no difference in carriage of any pneumococcus between
vaccinated and unvaccinated cohorts. However, the prevalence of
NVT carriage at 9 months was significantly higher in 7vPCV recip-
ients than in controls suggesting some impact of PCV on the pneu-
mococcal carriage populations in vaccinated children. It is likely
that the limited effect of 7vPCV on VT carriage is due to the high
density of carriage and diversity of serotypes circulating, with rel-
atively low prevalence of 7vPCV types; in the control cohort only
39% of carried isolates at 9 months of age were 7vPCV types.
We have previously reported immunogenicity to PCV7 in this
trial [17]. Geometric mean concentrations (GMTs) of serotype-
specific IgG levels for all VT were above the cut-off value of
0.35 lg/mL for protection from IPD. At age 4 months antibodyGMTs
were remarkably similar to those reported in Kenya following the
standard 6–10–14-week PCV schedule commonly used in third
world settings and also following the neonatal schedule trialled in
Kenya [17,21]. The more conservative value of 1 lg/mL was more
discriminatory as less than half of the samples at age 9 months
had a serotype-specific antibody titre P1 lg/mL for serotypes 4,
9V, 18C and23F.However, it is noteworthy that antibody titerswere
high at age 9 months for those serotypes that weremore commonly
isolated at age 3 months (6B, 14 and 19F), suggesting that carriage
boosts the antibody response. The proportion of samples with anti-
body titersP1 lg/mL inour studywashigher for all VTs thanamong
recipients of the standard EPI schedule in Kenya [21]. To our knowl-
edge there is no established correlate for protection against pneu-
mococcal carriage although 5 lg/mL was found by Goldblatt et al.
to be protective against serotype 14 carriage in adults in the United
Kingdom [31]. While theoretically administration of PPV at age
9 months may affect memory B cells numbers at age 18 months,
we have found circulating VT-specific memory B-cells are present
at 18 months and are not different to unvaccinated controls at age
3–5 years [32]. The relationship between carriage and immune
response to pneumococci requires further investigation.Our study had several limitations. Firstly, the study was origi-
nally powered to detect group differences in immune response
[17,18] and, consequently, some of the potentially important
observed differences in secondary outcomes such as carriage preva-
lence, do not reach statistical significance. For example, the keyfind-
ing of a difference in prevalence of VT at 9 months of age between
vaccinated (22%) and unvaccinated (31%) groups would require a
sample sizeof 278pergroup tohave80%power tobedetectedas sta-
tistically significant (p < 0.05). Thiswould involve the recruitmentof
approximately 350 infants per group whereas only around 100 per
group were actually enrolled. Secondly, the time points selected
for sampling may not have been optimal to detect impact of PCV
on carriage: age 3 months may have been too early to see an effect
on VT carriage while 9 months may have been too late. We saw a
non-significant difference in VT carriage between PCV recipients
and controls at age 9 months, but the impact of PCV on VT carriage
might have already peaked at age six months.
Not all samples could be cultured as samples were lost follow-
ing a freezer failure. Nevertheless 87% of samples (n = 1761) were
cultured and for 80% of children we had culture data from 5 or
more samples per child. Furthermore, we did not have factor type
sera for all serogroups and therefore could not serotype all isolates
(although some additional factor typing was available on isolates
characterised in Australia). Hence the serotype diversity is an
underestimate. Finally, in view of the wide diversity of serotypes
and the consequent small number of isolates across the serotypes,
we could not look at the impact of 7vPCV on individual serotypes.
The high and varied diversity in serotypes limits PCV coverage
and in turn increases the likelihood of replacement serotypes in
carriage and disease. Following the rollout of the 13vPCV in PNG
in 2014, it is vital to closely monitor carriage and invasive pneumo-
coccal disease serotypes to observe direct and population herd
effects of vaccine on serotype distribution. Serotype-independent
vaccines are needed to protect against pneumococcal disease irre-
spective of capsular serotype, but there is also a need to address
the underlying environmental factors and to determine the sources
of infection in children.Financial disclosure
This project was funded by an International Collaborative Pro-
ject Grant of the Wellcome Trust, United Kingdom (071613/Z/03/
Z) and the Australian National Health and Medical Research
Council (NHMRC #303123).
DL received funding from an NHMRC Program grant (#353514)
and a Project Grant (#572590). The funders had no role in study
design, data collection and analysis, decision to publish, or prepa-
ration of the manuscript. AJL is funded by an NHMRC Research
Fellowship (#1020561). CA is currently funded through an
Australia Awards Scholarship administered by the Australian
Department of Foreign Affairs and Trade.Authors’ contributions
The study was conceived and designed by DL, PCR, JR, with
microbiological input from AJL. DL, PCR, JR obtained the funding
to conduct the study. AG oversaw the microbiology. CA, AM, MY
conducted microbiological analysis and reviewed all microbiology
data. JR oversaw the implementation of the clinical trial and pro-
vided administrative support. AJL and HSV provided microbiologi-
cal expertise in preparation of the manuscript. SP supervised
enrolment, clinical follow-up, specimen collection and field work.
PN and GS did clinical follow-up and collected all NPS. PJ and DL
analysed the data. CA and DL drafted the manuscript. All authors
42 C. Aho et al. / Vaccine Reports 6 (2016) 36–43have critically read and approved the final version of the
manuscript.
Conflicts of Interest
AG, DL and WP have received research support through a Pfizer
Investigator Initiated Grant. DL has been a member of the
GlaxoSmithKline Australia Pneumococcal-Haemophilus influenzae-
Protein D conjugate vaccine Advisory Panel, has received support
from Pfizer Australia and GSK Australia to attend conferences, and
has received an honorarium fromMerck Vaccines to give a seminar
at their offices in Pennsylvania and to attend a conference. WP
received a travel grant from Pfizer Australia to attend the 8th Inter-
national Symposium on Pneumococci and Pneumococcal Diseases
(ISPPD) in 2012. AJL has received research support through Investi-
gator InitiatedGrants fromPfizer andGlaxoSmithKline. PR is amem-
ber of the Vaccine Trials Group, which has received funding from
vaccine manufacturers, including Pfizer, Sanofi Pasteur, BioCSL,
and GlaxoSmithKline. Other authors declare no conflict of interest.
Acknowledgements
We thank Helen Smith from the Brisbane Queensland Public
Health Laboratory for performing quality assurance on our pneu-
mococcal serotyping and Janice Lim for assistance in preparation
of the graphs.
List of institutions and investigators forming the Neonatal
Pneumococcal Conjugate Vaccine Study Team:
Papua New Guinea Institute of Medical Research: E. Aemamero,
C. Aho (also Menzies School of Health Research, Australia), M. Aku-
naii, H. Aole, E. Bilam, M. Dreyam, S. Eza’e, J. Francis, N. Fufu, A.
Greenhill (also Federation University, Churchill, Victoria, Aus-
tralia), E. Hasu, L. Helivi, G. Inapero, T. Jack, S. James, A Javati, H.
Keno, W. Kirarock, I. Ko’ezo, M. Lai, A. Lapiso, A.M. Laumaea, S. Mar-
aga, M. Martin, A. Michael, M. Michaels, A. Mope, B. Nivio, P. Ove, T.
Orami, N. Paul, S. Phuanukoonnon (also the Walter & Eliza Hall
Institute, Melbourne), G. Poigeno, W.S. Pomat, J. Reeder (also Bur-
net Institute, Melbourne), G. Saleu, R. Sehuko, P. Siba, V. Siba, A.
Sie, L. Sinke, J. Totave, B. Uro, G. Vengiau, L. Wawa’e, T. Wayaki,
M. Yoannes
Goroka General Hospital doctors: J. Ande, J. Apa, D. Frank, W.
Pame, N. Pomat, P. Keasu, A. Pikuri, H. Pok
Telethon Kids Institute, Perth, Western Australia: K.S Alpers, C.
Devitt, P.G. Holt, P. Jacoby, I. Laing (also the University of Western
Australia), D. Lehmann, M. Nadal-Sims, A. van den Biggelaar
School of Paediatrics and Child Health, the University of Wes-
tern Australia: P.C. Richmond
PathWest Laboratory Medicine, Western Australia: G. Chidlow,
J. Harnett, D.W. Smith (also the University of Western Australia)
Curtin University: M.P. Alpers
Menzies School of Health Research: A.J. Leach, H. Smith-
Vaughan
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.vacrep.2016.08.
002.
References
[1] L. Liu, S. Oza, D. Hogan, J. Perin, I. Rudan, J.E. Lawn, et al., Global, regional, and
national causes of child mortality in 2000–13, with projections to inform post-
2015 priorities: an updated systematic analysis, Lancet 385 (2015) 430–440.
[2] K.L. O’Brien, L.J. Wolfson, J.P. Watt, E. Henkle, M. Deloria-Knoll, N. McCall, et al.,
Burden of disease caused by Streptococcus pneumoniae in children younger
than 5 years: global estimates, Lancet 374 (2009) 893–902.[3] W. Sun, P. Jacoby, T.V. Riley, J. Bowman, A.J. Leach, H. Coates, et al., Association
between early bacterial carriage and otitis media in Aboriginal and non-
Aboriginal children in a semi-arid area of Western Australia: a cohort study,
BMC Infect. Dis. 12 (2012) 366.
[4] J.M. Montgomery, D. Lehmann, T. Smith, A. Michael, B. Joseph, T. Lupiwa, et al.,
Bacterial colonization of the upper respiratory tract and its association with
acute lower respiratory tract infections in highland children of Papua New
Guinea, Rev. Infect. Dis. 12 (Suppl 8) (1990) S1006–S1016.
[5] M. Gratten, H. Gratten, A. Poli, E. Carrad, M. Raymer, G. Koki, Colonisation of
Haemophilus influenzae and Streptococcus pneumoniae in the upper respiratory
tract of neonates in Papua New Guinea: primary acquisition, duration of
carriage, and relationship to carriage in mothers, Biol. Neonate 50 (1986) 114–
120.
[6] J.P. Francis, P.C. Richmond, W.S. Pomat, A. Michael, H. Keno, S. Phuanukoonnon,
et al., Maternal antibodies to pneumolysin but not to pneumococcal surface
protein A delay early pneumococcal carriage in high-risk Papua New Guinean
infants, Clin. Vaccine Immunol. 16 (2009) 1633–1638.
[7] Papua New Guinea Department of Health, Papua New Guinea Child Health
Policy and Plan 2009–2020, Port Moresby: Department of Health, 2009.
[8] T. Duke, A. Michael, J. Mgone, D. Frank, T. Wal, R. Sehuko, Etiology of child
mortality in Goroka, Papua New Guinea: a prospective two-year study, Bull.
WHO 80 (2002) 16–25.
[9] M. Kakazo, D. Lehmann, K. Coakley, H. Gratten, G. Saleu, J. Taime, et al.,
Mortality rates and the utilization of health services during terminal illness in
the Asaro Valley, Eastern Highlands Province, Papua New Guinea, PNG Med. J.
42 (1999) 13–26.
[10] K.L. O’Brien, E.V. Millar, E.R. Zell, M.A. Bronsdon, R. Weatherholtz, R. Reid, et al.,
Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization
among immunized and unimmunized children in a community-randomised
trial, J. Infect. Dis. 196 (2007) 1211–1220.
[11] R. Singleton, J. Wenger, J.A. Klejka, L.R. Bulkow, A. Thompson, D. Sarkozy, et al.,
The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal
disease in Alaska native children: results of a clinical trial, Pediatr. Infect. Dis. J.
32 (2013) 257–263.
[12] C.G. Whitney, M.M. Farley, J. Hadler, L.H. Harrison, N.M. Bennett, R. Lynfield,
et al., Decline in invasive pneumococcal disease after the introduction of
protein-polysaccharide conjugate vaccine, N. Engl. J. Med. 348 (2003) 1737–
1746.
[13] F.T. Cutts, S.M. Zaman, G. Enwere, S. Jaffar, O.S. Levine, J.B. Okoko, et al.,
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia
and invasive pneumococcal disease in The Gambia: randomised, double-blind,
placebo-controlled trial, Lancet 365 (2005) 1139–1146.
[14] K.P. Klugman, S.A. Madhi, R.E. Huebner, R. Kohberger, N. Mbelle, N. Pierce,
et al., A trial of a 9-valent pneumococcal conjugate vaccine in children with
and those without HIV infection, N. Engl. J. Med. 349 (2003) 1341–1348.
[15] N. Mbelle, R.E. Huebner, A.D. Wasas, A. Kimura, I. Chang, K.P. Klugman,
Immunogenicity and impact on nasopharyngeal carriage of a nonavalent
pneumococcal conjugate vaccine, J. Infect. Dis. 180 (1999) 1171–1176.
[16] I.D. Riley, D. Lehmann, M.P. Alpers, T.F. De C Marshall, H. Gratten, D. Smith,
Pneumococcal vaccine prevents death from acute lower respiratory-tract
infections in Papua New Guinean children, Lancet 2 (1986) 877–881.
[17] W.S. Pomat, A.H. van den Biggelaar, S. Phuanukoonnon, J. Francis, P. Jacoby, P.
M. Siba, et al., Safety and immunogenicity of neonatal pneumococcal
conjugate vaccination in Papua New Guinean children: a randomised
controlled trial, PLoS ONE 8 (2013) e56698.
[18] S. Phuanukoonnon, J.C. Reeder, W.S. Pomat, A.H. van den Biggelaar, P.G. Holt, G.
Saleu, et al., A neonatal pneumococcal conjugate vaccine trial in Papua New
Guinea: study population, methods and operational challenges, PNG Med. J. 53
(2010) 191–206. Available at: http://www.pngimr.org.pg/png_med_journal/
sept-dec%202010%20a%20neonatal%20pneumococcal%20conjugate%20vaccine%
20trials%20in%20png.pdf. Accessed 17 March 2016.
[19] Papua New Guinea Department of Health. Standard treatment for common
illnesses of children in Papua New Guinea. A manual for nurses, community
health workers, health extension officers and doctors. Port Moresby:
Department of Health; 2005.
[20] C. Satzke, P. Turner, A. Virolainen-Julkunen, P.V. Adrian, M. Antonio, K.M. Hare,
et al., Standard method for detecting upper respiratory carriage of
Streptococcus pneumoniae: updated recommendations from the World Health
Organization Pneumococcal Carriage Working Group, Vaccine 32 (2013) 165–
179.
[21] J.A. Scott, J. Ojal, L. Ashton, A. Muhoro, P. Burbidge, D. Goldblatt, Pneumococcal
conjugate vaccine given shortly after birth stimulates effective antibody
concentrations and primes immunological memory for sustained infant
protection, Clin. Infect. Dis. 53 (2011) 663–670.
[22] S.K. Obaro, R.A. Adegbola, W.A. Banya, B.M. Greenwood, Carriage of
pneumococci after pneumococcal vaccination, Lancet 348 (1996) 271–272.
[23] E.M. Dunne, J. Manning, F.M. Russell, R.M. Robins-Browne, E.K. Mulholland, C.
Satzke, Effect of pneumococcal vaccination on nasopharyngeal carriage of
Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and
Staphylococcus aureus in Fijian children, J. Clin. Microbiol. 50 (2012) 1034–
1038.
[24] H. Smith-Vaughan, R. Byun, M. Nadkarni, N.A. Jacques, N. Hunter, S. Halpin,
et al., Measuring nasal bacterial load and its association with otitis media, BMC
Ear Nose Throat Disord. 6 (2006) 10.
[25] P. Jacoby, K.S. Carville, G. Hall, T.V. Riley, J. Bowman, A.J. Leach, et al., Crowding
and other strong predictors of upper respiratory tract carriage of otitis media-
C. Aho et al. / Vaccine Reports 6 (2016) 36–43 43related bacteria in Australian Aboriginal and non-Aboriginal children, Pediatr.
Infect. Dis. J. 30 (2011) 480–485.
[26] R. Grimley, Chronic lung disease in a highland valley of Papua New Guinea [B
Med Sci], University of Queensland, Brisbane, 1988.
[27] W.K. Kirarock, Oxidative stress and inflammatory responses in pregnant
women and newborns exposed prenatally to high levels of indoor air pollution
in the highlands of Papua New Guinea [Bachelor of Science Honours],
University of Papua New Guinea, Port Moresby, 2010.
[28] D. Greenberg, N. Givon-Lavi, A. Broides, I. Blancovich, N. Peled, R. Dagan, The
contribution of smoking and exposure to tobacco smoke to Streptococcus
pneumoniae and Haemophilus influenzae carriage in children and their mothers,
Clin. Infect. Dis. 42 (2006) 897–903.
[29] O.R. El Ahmer, S.D. Essery, A.T. Saadi, M.W. Raza, M.M. Ogilvie, D.M. Weir, et al.,
The effect of cigarette smoke on adherence of respiratory pathogens to buccal
epithelial cells, FEMS Immunol. Med. Microbiol. 23 (1999) 27–36.[30] E. Stubbs, K. Hare, C. Wilson, P. Morris, A.J. Leach, Streptococcus pneumoniae
and noncapsular Haemophilus influenzae nasal carriage and hand
contamination in children: a comparison of two populations at risk of otitis
media, Pediatr. Infect. Dis. J. 24 (2005) 423–428.
[31] D. Goldblatt, M. Hussain, N. Andrews, L. Ashton, C. Virta, A. Melegaro, et al.,
Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in
adults: a longitudinal household study, J. Infect. Dis. 192 (2005) 387–393.
[32] P. Richmond, W. Pomat, A. Fuery, J. Francis, C. Opa, P. Siba, et al., Pneumococcal
polysaccharide vaccine at 9 months of age is not associated with impaired B-
cell memory or hyporesponsiveness in children in PNG [Abstract ISPPD -
0370], Pneumonia 3 (2014) 226.
